NeurAxis, Inc. (NRXS)

NeurAxis reported a 27% year-over-year increase in Q4 2025 revenue and a 33% increase for the full year 2025. A Category I CPT® Code for PENFS procedures was implemented, establishing a permanent reimbursement pathway. The company announced new medical policy coverage from a major national health insurer for PENFS, adding approximately 45 million covered lives. NeurAxis reported a 22% year-over-year increase in revenues for Q3 2025. The FDA clearance for IB-Stim was expanded to include functional dyspepsia and nausea in patients aged 8 years and older, and to allow for up to four devices per patient. As of March 24, 2026, the stock price was $7.05 per share, marking a substantial increase of 221.92% from $2.19 per share on March 25, 2025.

There is no specific information available regarding demand seasonality for NeurAxis, Inc.'s products and services. Demand may be less subject to seasonal fluctuations compared to products or services addressing acute or seasonal ailments.

NeurAxis, Inc. is a medical technology company specializing in neuromodulation therapies for disorders of the gut-brain interaction (DGBI). Its primary product, IB-Stim, utilizes Percutaneous Electrical Nerve Field Stimulation (PENFS) technology and is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional dyspepsia (FD) in patients aged 8 years and older. The company's second product, the Rectal Expulsion Device (RED), is a diagnostic tool used to evaluate neuromuscular function related to rectal expulsion and to identify rectal hypersensitivity. NeurAxis aims to advance its science and leverage evidence-based medicine to promote the adoption of its therapies.

NeurAxis, Inc. is headquartered in Carmel, Indiana, with a distribution center in Versailles, Indiana, primarily focusing its operations within the United States. The company also collaborates with international partners to support its translational and clinical development activities.

NeurAxis's brand reputation appears to be positively influenced by its focus on scientific advancement and regulatory achievements. The expanded FDA clearances for IB-Stim and the establishment of a Category I CPT code have bolstered its reputation. Securing significant new medical policy coverage from a major national health insurer for its PENFS technology further enhances its standing.

Institutional investors hold 11.77% of NeurAxis, Inc.'s stock, company insiders own 29.34%, and retail investors account for 56.61%. Major institutional owners include AIGH Capital Management LLC, Rosalind Advisors, Inc., Money Concepts Capital Corp, Panoramic Capital, LLC, Vanguard Group Inc, Parsons Capital Management Inc/ri, Geode Capital Management, Llc, UBS Group AG, State Street Corp and Northern Trust Corp. Key individual owners include Brian Hannasch, Christopher Robin Brown, and Gil Aharon.